FDA expands use of rivaroxaban to treat, reduce recurrence of DVT, PE


FDA has expanded the approved use of oral anticoagulant rivaroxaban (Xarelto, Janssen) for to include 3 new indications including treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial treatment.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.